Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
- 3 January 2012
- journal article
- review article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 122 (1), 4-12
- https://doi.org/10.1172/jci60016
Abstract
The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor–null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose-responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.Keywords
This publication has 101 references indexed in Scilit:
- Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetesBMC Genomics, 2011
- Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axisJCI Insight, 2011
- Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell massAmerican Journal of Physiology-Endocrinology and Metabolism, 2011
- Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in miceProceedings of the National Academy of Sciences of the United States of America, 2010
- Paracrinology of islets and the paracrinopathy of diabetesProceedings of the National Academy of Sciences of the United States of America, 2010
- Glucose Suppression of Glucagon SecretionOnline Journal of Public Health Informatics, 2010
- Leptin therapy in insulin-deficient type I diabetesProceedings of the National Academy of Sciences of the United States of America, 2010
- Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulationPeptides, 2009
- The Glucagon Receptor Is Required for the Adaptive Metabolic Response to FastingCell Metabolism, 2008
- Making insulin-deficient type 1 diabetic rodents thrive without insulinProceedings of the National Academy of Sciences of the United States of America, 2008